Emerging drugs for the treatment of Dravet syndrome-Reference-Cited by-同舟云学术

Emerging drugs for the treatment of Dravet syndrome

Published:2018-10-02 Issue:4 Volume:23 Page:261-269
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

Brigo Francesco¹²^ORCID,Striano Pasquale³^ORCID,Balagura Ganna³,Belcastro Vincenzo⁴^ORCID

Affiliation:

1. Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

2. Division of Neurology, “Franz Tappeiner” Hospital, Merano, Italy

3. Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, “G. Gaslini” Institute, Genova, Italy

4. Neurology Unit, S. Anna Hospital, Como, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728214.2018.1552937

Reference62 articles.

1. Early diagnosis of severe myoclonic epilepsy in infancy

2. Epidemiology of Severe Myoclonic Epilepsy of Infancy

3. De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy

4. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials;Frontiers in Neurology;2024-03-25

2. Antisense Molecules in Epilepsy—A Neuropharmacological Educational Review;International Journal of Epilepsy;2022-10

3. Current and promising therapeutic options for Dravet syndrome;Expert Opinion on Pharmacotherapy;2022-09-21

4. Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine;Frontiers in Pharmacology;2022-05-20

5. Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome;The Neuroscientist;2022-04-13